Maze Therapeutics (MAZE) Net Cash Flow (2024 - 2026)

Maze Therapeutics' Net Cash Flow history spans 3 years, with the latest figure at $9.5 million for Q1 2026.

  • On a quarterly basis, Net Cash Flow fell 90.24% to $9.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$95.6 million, a 136.17% decrease, with the full-year FY2025 number at -$7.6 million, down 104.51% from a year prior.
  • Net Cash Flow hit $9.5 million in Q1 2026 for Maze Therapeutics, up from -$127.5 million in the prior quarter.
  • Over the last five years, Net Cash Flow for MAZE hit a ceiling of $145.0 million in Q2 2024 and a floor of -$127.5 million in Q4 2025.
  • Historically, Net Cash Flow has averaged $18.8 million across 3 years, with a median of $9.5 million in 2026.
  • The widest YoY moves for Net Cash Flow: up 11178.96% in 2025, down 370.16% in 2025.
  • Tracing MAZE's Net Cash Flow over 3 years: stood at $47.2 million in 2024, then tumbled by 370.16% to -$127.5 million in 2025, then soared by 107.46% to $9.5 million in 2026.
  • Business Quant data shows Net Cash Flow for MAZE at $9.5 million in Q1 2026, -$127.5 million in Q4 2025, and $52.2 million in Q3 2025.